

NB: this is a **summary translation** of the press release original drafted in Japanese for the disclosure in compliance with the TSE regulations. In case of any discrepancy, the Japanese original shall prevail.

14 Nov 2017

Oncolys BioPharma Inc.

Oncolys entered into a Joint Research Agreement with Juntendo University for TelomeScan (OBP-401/OBP-1101)

Oncolys BioPharma (“Oncolys”) is pleased to announce that it signed a joint research agreement with Juntendo University, Tokyo, to develop a highly sensitive tumor detection test and system using TelomeScan (OBP-401/OBP-1101), Oncolys’ new specific gene-modified adenovirus for cancer detection. The project will be conducted by a research group led by Dr. Shinsaku Togo, Division of Respiratory Medicine, Department of Internal Medicine, School of Medicine at Juntendo University. The goal of the research is an automation of tumor detection using TelomeScan aiming at its practical use in clinical settings and to establish its clinical significance.

Despite the widely held view that detecting circulating tumor cells (“CTCs”) of non-small-cell lung cancer (“NSCLC”) patients with current technology is challenging, the recent study*ⁱ by Dr. Togo’s group has already and successfully shown that TelomeScan can detect viable CTCs of NSCLC, including those with epithelial-mesenchymal transition status (EMT-CTCs). Oncolys and Juntendo University expect that TelomeScan will be a useful tool for early diagnosis of NSCLC patients, and for medical doctors to make decisions on therapeutic options, monitoring efficacy and prognosis of the treatment and through genetic analysis of CTCs.

The announcement above will not affect Oncolys’ earnings for the fiscal year ending 31 December 2017.

Ends

###

About Oncolys BioPharma Inc.

Oncolys BioPharma is a TSE Mothers-listed biopharmaceutical company with focuses on the development of novel biologics for the treatment of cancer and infectious diseases. The company’s lead product for the treatment of cancer, Telomelysin® (OBP-301), is based on replication-competent oncolytic virus, and is being tested in Phase I/II clinical trial in Asia and Phase II in the USA, for various solid tumors. A novel cancer diagnostic product, TelomeScan® (OBP-401/1101), is expected to be effective as companion diagnostic tool in detecting various types of cancer and inflammatory diseases and adopted in several private practices. The company also has a major program OBP-601

(Censavudine) for infectious diseases, for which it completed Phase II clinical trial in the U.S. for HIV/AIDS therapy, supported by BMS. For more information, please visit <http://www.oncolys.com/en/>

Oncolys BioPharma Inc.	
Mie Yamazaki Investor Relations & Corporate Communications Tel: +81 (0) 5472 1578 Email: yamazaki@oncolys.com	

*i Oncotarget. 2017 May 23;8(21):34884-34895. doi: 10.18632/oncotarget.16818.

TRANSLATION